155 related articles for article (PubMed ID: 24271525)
1. Pharmacokinetics and reversible biotransformation of sulfinpyrazone and its metabolites in rabbits. I. Single-dose study.
Ritschel WA
Pharm Res; 1986 Jun; 3(3):173-7. PubMed ID: 24271525
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetics and Reversible Biotransformation of Sulfinpyrazone and Its Metabolites in Rabbits. II. Multiple-Dose Study.
Kuo BS; Ritschel WA
Pharm Res; 1986 Jun; 3(3):178-83. PubMed ID: 24271526
[TBL] [Abstract][Full Text] [Related]
3. Correlation between inhibitory effect on platelet aggregation and disposition of sulfinpyrazone and its metabolites in rabbits. Part I: Single dose study.
Ritschel WA; Kuo BS
Biopharm Drug Dispos; 1987; 8(1):1-9. PubMed ID: 3107626
[TBL] [Abstract][Full Text] [Related]
4. New metabolites of sulfinpyrazone in man.
Dieterle W; Faigle JW; Moppert J
Arzneimittelforschung; 1980; 30(6):989-93. PubMed ID: 7191279
[TBL] [Abstract][Full Text] [Related]
5. Species differences in the disposition and metabolism of sulfinpyrazone.
Dieterle W; Faigle JW
Xenobiotica; 1981 Aug; 11(8):559-68. PubMed ID: 7303725
[TBL] [Abstract][Full Text] [Related]
6. Correlation between inhibitory effect on platelet aggregation and disposition of sulfinpyrazone and its metabolites in rabbits. Part II: Multiple dose study.
Kuo BS; Ritschel WA
Biopharm Drug Dispos; 1987; 8(1):11-21. PubMed ID: 3580509
[TBL] [Abstract][Full Text] [Related]
7. Kinetics and metabolism of sulfinpyrazone.
Mahony C; Wolfram KM; Nash PV; Bjornsson TD
Clin Pharmacol Ther; 1983 Apr; 33(4):491-7. PubMed ID: 6831828
[TBL] [Abstract][Full Text] [Related]
8. Biotransformation and pharmacokinetics of sulfinpyrazone (Anturan) in man.
Dieterle W; Faigle JW; Mory H; Richter WJ; Theobald W
Eur J Clin Pharmacol; 1975 Dec; 9(2-3):135-45. PubMed ID: 786687
[TBL] [Abstract][Full Text] [Related]
9. Determinants of the pharmacokinetics of antithrombotic drugs.
Marks GS
Thromb Res Suppl; 1983; 4():17-27. PubMed ID: 6356463
[TBL] [Abstract][Full Text] [Related]
10. High-performance liquid chromatographic determination of sulfinpyrazone and its metabolites in plasma.
Kuo BS; Kaplan LA; Ritschel WA
Arzneimittelforschung; 1984; 34(5):548-50. PubMed ID: 6540568
[TBL] [Abstract][Full Text] [Related]
11. Role of the gut flora in the reduction of sulfinpyrazone in humans.
Strong HA; Oates J; Sembi J; Renwick AG; George CF
J Pharmacol Exp Ther; 1984 Sep; 230(3):726-32. PubMed ID: 6470977
[TBL] [Abstract][Full Text] [Related]
12. Plasma levels of sulfinpyrazone and of two of its metabolites after a single dose and during the steady state.
Rosenkranz B; Fischer C; Jakobsen P; Kirstein Pedersen A; Frölich JC
Eur J Clin Pharmacol; 1983; 24(2):231-5. PubMed ID: 6840173
[TBL] [Abstract][Full Text] [Related]
13. Enterohepatic recirculation model of irinotecan (CPT-11) and metabolite pharmacokinetics in patients with glioma.
Younis IR; Malone S; Friedman HS; Schaaf LJ; Petros WP
Cancer Chemother Pharmacol; 2009 Feb; 63(3):517-24. PubMed ID: 18496691
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetics of ethylene glycol. III. Plasma disposition and metabolic fate after single increasing intravenous, peroral, or percutaneous doses in the male Sprague-Dawley rat.
Frantz SW; Beskitt JL; Tallant MJ; Zourelias LA; Ballantyne B
Xenobiotica; 1996 May; 26(5):515-39. PubMed ID: 8736063
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of (S)-warfarin metabolism by sulfinpyrazone and its metabolites.
He M; Kunze KL; Trager WF
Drug Metab Dispos; 1995 Jun; 23(6):659-63. PubMed ID: 7587949
[TBL] [Abstract][Full Text] [Related]
16. The effect of sulfinpyrazone on the disposition of pseudoracemic phenprocoumon in humans.
Heimark LD; Toon S; Gibaldi M; Trager WF; O'Reilly RA; Goulart DA
Clin Pharmacol Ther; 1987 Sep; 42(3):312-9. PubMed ID: 3621786
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetics of sulphinpyrazone and its major metabolites after a single dose and during chronic treatment.
Schlicht F; Staiger C; de Vries J; Gundert-Remy U; Hildebrandt R; Harenberg J; Wang NS; Weber E
Eur J Clin Pharmacol; 1985; 28(1):97-103. PubMed ID: 3987792
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of human platelet cyclo-oxygenase activity by sulfinpyrazone and three of its metabolites.
Del Maschio A; Livio M; Cerletti C; De Gaetano G
Eur J Pharmacol; 1984 Jun; 101(3-4):209-14. PubMed ID: 6432556
[TBL] [Abstract][Full Text] [Related]
19. Determination of sulfinpyrazone and four metabolites in plasma and urine by high pressure liquid chromatography.
Lentjes EG; Tan Y; Van Ginneken CA
Pharm Weekbl Sci; 1985 Dec; 7(6):252-9. PubMed ID: 4080510
[TBL] [Abstract][Full Text] [Related]
20. Disposition kinetics of ML-1035 sulfoxide enantiomers and the prochiral sulfide in rats.
Kuo BS; Poole JC; Mandagere AK; Hwang KK
Chirality; 1993; 5(6):428-35. PubMed ID: 8398602
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
